At the cutting edge

At the
cutting edge.

Research for life

Research
for life.

Innovation and performance

Innovation and
performance.

Latest

Whats new.

June 23rd 2025

Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
May 26th 2025

Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
May 15th 2025

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
more

Upcoming Events

Whats next.

September 6th 2025 - September 9th 2025

read more
October 17th 2025 - October 21st 2025

read more

Who we are

About us.

passion.

It takes a great deal of passion on the fight against cancer. We put our heart and soul into winning it.

know-how.

Our goal is to gather the strongest forces, the brightest minds and the most dedicated employees.

research.

Accurate research is the strong foundation for developing potential in effective treatment.

What is LAG3?
Lymphocyte-activation gene 3, or LAG-3 (LAG3), is a cell surface molecule with biologic effects on T cell function.
LAG3 is being used for many cancer immunotherapy treatments including Eftilagimod Alpha from Immutep.